Remaeus K, Johansson K, Granath F, et al. - In this Swedish nationwide register-based cohort study, pregnancy outcomes were examined in relation to antirheumatic treatment before and during pregnancy as a proxy of disease severity in PsA-pregnancies as compared with non-PsA-pregnancies.

• Included were 921 PsA- pregnancies and 9,210 non-PSA-pregnancies (matched 1:10 on maternal age, year, and parity).

• Relative to women with non-PsA-pregnancies, those with PsA-pregnancies were more frequently obese, more often smokers and had a diagnosis of pre-gestational hypertension and diabetes.

• In comparison with non-PsA-pregnancies, those exposed to antirheumatic treatment during pregnancy, especially biologics, are mostly at increased risks of preterm birth and cesarean delivery.

• Findings support providing special attention to first pregnancies given the influence of parity on the risk of preterm birth in PsA pregnancies.

• During pregnancy, individualized monitoring should be done in women with PsA.